Key result
HeLa CCL-2 cells returned Coxsackievirus B3/28 titers that were more than ten-fold lower than those obtained using laboratory HeLa cells, highlighting significant cell line heterogeneity.
Differences in HeLa cell strain histories can lead to significant inter-laboratory variability in coxsackievirus B3 cytopathic effect and viral titers.
Cell line heterogeneity may confound CVB3 titer interpretation; leaves open need for standardized authentication in enterovirus research.
Concerns over cell line identities and contamination have led investigators to acquire fresh stocks of HeLa CCL-2 cells, but results with the HeLa CCL-2 cells do not always reproduce results with HeLa cells that have long history in the laboratory. When used for TCID(50) assays of Coxsackievirus B3/28 (CVB3/28), HeLa CCL-2 cells returned titers for CVB3/28 that were more than ten-fold lower than titers obtained using laboratory HeLa cells. The viral cytopathic effect was less distinct in the HeLa CCL-2 cultures, suggestive of a mixed population of cells with varied susceptibility to viral cytopathic effect. Analysis of short tandem repeat markers confirmed the identities of the cell lines as HeLa. Subpopulations in the HeLa CCL-2 culture, separated easily based on the speed with which they were released by trypsin-EDTA, differed in their susceptibilities to CVB3/28 cytopathic effect, and in their expression of the Coxsackievirus and adenovirus receptor (CAR). The distinctions between Lab HeLa and HeLa CCL-2 cells were less obvious when infected with CVB3/RD, a strain selected for growth in RD cells. Results that differ among laboratories may be due to the use of HeLa cell strains with different histories, and experiments using HeLa CCL-2 available from the American Type Culture Collection are probably incapable of reproducing many of the published studies of Coxsackievirus that have used HeLa cells with laboratory-dependent histories.
No takes yet. Share an insight, caveat, or question.
Carson et al. (2013) studied Coxsackievirus B3 infection. HeLa CCL-2 cells vs. Laboratory HeLa cells was evaluated on Viral titers for CVB3/28 (TCID50 assays). HeLa CCL-2 cells returned Coxsackievirus B3/28 titers that were more than ten-fold lower than those obtained using laboratory HeLa cells, highlighting significant cell line heterogeneity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: